Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20853317rdf:typepubmed:Citationlld:pubmed
pubmed-article:20853317lifeskim:mentionsumls-concept:C0021344lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0950124lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0205064lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0038951lld:lifeskim
pubmed-article:20853317lifeskim:mentionsumls-concept:C0039260lld:lifeskim
pubmed-article:20853317pubmed:issue5lld:pubmed
pubmed-article:20853317pubmed:dateCreated2011-1-4lld:pubmed
pubmed-article:20853317pubmed:abstractTextHuman papillomavirus (HPV) causes cervical neoplasia; but limited data are available from Asia. We conducted a large-scale community-based cohort study in Taiwan to estimate prevalence of genotype-specific HPV infection and cervical neoplasia. Following written informed consent, cervical cells for cytology and HPV testing were collected from 11,923 participants (aged 30-65 years old, mean 46.3) in 1991-1992. Genotyping was performed using MY11/GP6+ PCR-based HPV Blot (EasyChip) for 39 HPV types. The overall HPV prevalence was 16.2% for 10,602 eligible participants, and 13.8% for 10,190 cytologically normal participants. The most common carcinogenic types were HPV52 (2.5%), HPV16 (2.0%), HPV56 (1.8%), HPV18 (1.6%), HPV33 (1.2%), HPV58 (1.3%) and HPV39 (1.0%). Among the 56 prevalent invasive and in situ cases, HPV16 (48.2%) was most common, followed by HPV58 (25.0%), HPV52 (19.6%), HPV31 (8.9%), HPV33 (8.9%) and HPV18 (3.6%). HPV16 and HPV58 caused cytological HSIL+ at younger ages than HPV52. Approximately half of the cervical cancer cases and high-grade precursors in Taiwan could be prevented by prophylactic vaccines against HPV16 and HPV18 infection. Up to 40% more could be prevented by targeting HPV58, HPV52, HPV33 and HPV31, arguing for the introduction of vaccines including more types.lld:pubmed
pubmed-article:20853317pubmed:languageenglld:pubmed
pubmed-article:20853317pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20853317pubmed:citationSubsetIMlld:pubmed
pubmed-article:20853317pubmed:statusMEDLINElld:pubmed
pubmed-article:20853317pubmed:monthMarlld:pubmed
pubmed-article:20853317pubmed:issn1097-0215lld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:SchiffmanMark...lld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:ChenChien-Jen...lld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:HsiehChang-Ya...lld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:LiawKai-LiKLlld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:HsingAnn WAWlld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:YouSan-LinSLlld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:LinChing-YuCYlld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:PanMei-HungMHlld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:ChenHui-ChiHClld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:ChouYi-ChunYClld:pubmed
pubmed-article:20853317pubmed:authorpubmed-author:CBCSP-HPV...lld:pubmed
pubmed-article:20853317pubmed:copyrightInfoCopyright © 2010 UICC.lld:pubmed
pubmed-article:20853317pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20853317pubmed:day1lld:pubmed
pubmed-article:20853317pubmed:volume128lld:pubmed
pubmed-article:20853317pubmed:ownerNLMlld:pubmed
pubmed-article:20853317pubmed:authorsCompleteYlld:pubmed
pubmed-article:20853317pubmed:pagination1192-203lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:meshHeadingpubmed-meshheading:20853317...lld:pubmed
pubmed-article:20853317pubmed:year2011lld:pubmed
pubmed-article:20853317pubmed:articleTitlePrevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women.lld:pubmed
pubmed-article:20853317pubmed:affiliationGenomics Research Center, Academia Sinica, Taipei, Taiwan.lld:pubmed
pubmed-article:20853317pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20853317pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed